ArticleNature metabolism2025
A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8
Abstract read
In one paragraph
Article in Nature metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- A comprehensive discovery platform for ELOVL1 small-molecule inhibitors targeting very long-chain fatty acid synthesis in adrenoleukodystrophy.The Journal of biological chemistry · 2026Article
- ELOVL1 promotes the progression of intrahepatic cholangiocarcinoma by enhancing endoplasmic reticulum stress and the PI3K/AKT/mTOR signaling pathway.Biology direct · 2026Article
- Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment.Cellular & molecular immunology · 2026Review
- A novel risk model of cholesterol metabolism-related mRNAs for predicting overall survival and immune signature in glioma based on machine learning and multi-omics data.Translational cancer research · 2026Article
- Targeting organelle function in T cells for cancer immunotherapy.Nature reviews. Immunology · 2026Review
- Redirecting Cholesterol Metabolism DuringInternational journal of biological sciences · 2026Article
- Development and validation of an interpretable machine learning model identify the lactylation-related protein SUSD3 as a prognostic and therapeutic biomarker for breast cancer.Frontiers in immunology · 2026Article
- Metabolic Checkpoints in CD8International journal of biological sciences · 2026Review
- Metabolic adaptations in cancer progression.Physiological reviews · 2026Review
- Mitochondria and lysosomes in T cell immunometabolism.Trends in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Samantha PrettoLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Qian Yu *Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Pierre Bourdely *Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4162-1490
Sarah Trusso CafarelloLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Heleen H Van AckerLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Joren VerelstLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0001-8332-9992
Elena RichiardonePole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium.
Lotte VanheerLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0003-1427-6131
Amir RoshanzadehDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.
Franziska SchneppenheimInstitute of Experimental Oncology (IEO), University Hospital Bonn, University of Bonn, Bonn, Germany.ORCID http://orcid.org/0009-0001-9545-5192
Charlotte CresensMolecular Imaging and Photonics Division, Chemistry Department, Faculty of Sciences, KU Leuven, Heverlee, Belgium.
Maria Livia SassanoCell Death Research and Therapy Group, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Jonas DehairsLaboratory of Lipid Metabolism and Cancer, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-6789-2264
Martin CarionDepartment of Chemistry, KU Leuven, Heverlee, Belgium.
Shehab IsmailDepartment of Chemistry, KU Leuven, Heverlee, Belgium.ORCID http://orcid.org/0000-0002-4150-1077
Patrizia AgostinisCell Death Research and Therapy Group, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-1314-2115
Susana RochaMolecular Imaging and Photonics Division, Chemistry Department, Faculty of Sciences, KU Leuven, Heverlee, Belgium.ORCID http://orcid.org/0000-0003-1258-9396
Tobias BaldInstitute of Experimental Oncology (IEO), University Hospital Bonn, University of Bonn, Bonn, Germany.
Johan SwinnenLaboratory of Lipid Metabolism and Cancer, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-7720-5077
Cyril CorbetPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium.ORCID http://orcid.org/0000-0001-8795-9131
Sophia Y LuntDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.ORCID http://orcid.org/0000-0003-4522-6065
Bernard ThienpontLaboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-8772-6845
Mario Di MatteoLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Massimiliano MazzoneLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium. Massimiliano.Mazzone@kuleuven.be.ORCID http://orcid.org/0000-0001-8824-4015
Funding
Examining PHGDH-mediated activation of sialic acid metabolism to drive triple-negative breast cancer metastasisR01CA270136 · NCI · MICHIGAN STATE UNIVERSITY · PI Sophia Lunt · 2022 to 2026
$2.0MMechanistic role of obesity in benzo(a)pyrene-initiated cancerR01ES030695 · NIEHS · MICHIGAN STATE UNIVERSITY · PI BERNARD, JAMIE J · 2020 to 2023
$1.5MEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ImmunoFit 773208Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1121223NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1S68422NMelanoma Research Alliance (MRA) 693786National Science Foundation (NSF) CBET 1845006NCI NIH HHS R01 CA270136NIEHS NIH HHS R01 ES030695Stichting Tegen Kanker (Belgian Foundation Against Cancer) F/2020/1544U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA270136U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) R01ES030695
Abstract
Reprogramming T cell metabolism can improve intratumoural fitness. By performing a CRISPR/Cas9 metabolic survey in CD8
Indexed as
CD8-Positive T-LymphocytesFatty Acid ElongasesNeoplasmsAnimalsFatty AcidsHumansMelanomaMicePancreatic NeoplasmsSingle-Cell AnalysisTumor MicroenvironmentFatty Acid ElongasesFatty Acids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.